The United States Food and Drug Administration approved the use of the GlaxoSmithKline drug Hycamtin in combination with cisplatin to treat late-stage cervical cancer in patients where surgery and radiation cannot help.
Hycamtin was initially approved by the FDA in 1996 for the treatment of ovarian cancer and small cell lung cancer. Cisplatin is used to treat a variety of tumors. Glaxo has dual U.S. headquarters in Research Triangle Park and Philadelphia. The company employs about 5,600 Triangle workers.
